Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 161 to 170 of 611 total matches.

Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
-lactamases (ESBLs) and carbapenemases, particularly among Enterobacterales.1 Products that combine ...
The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms (see Spectrum of Activity). Exblifep is the first product that contains enmetazobactam to be approved in the US.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):117-8   doi:10.58347/tml.2024.1707d |  Show IntroductionHide Introduction

Palopegteriparatide (Yorvipath) for Hypoparathyroidism

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
), a parathyroid hormone (PTH) 1-34 analog, has been approved by the FDA for treatment of hypoparathyroidism ...
Palopegteriparatide (Yorvipath – Ascendis), a parathyroid hormone (PTH) 1-34 analog, has been approved by the FDA for treatment of hypoparathyroidism in adults. The parathyroid hormone analog teriparatide (Forteo, and others), which is approved for treatment of postmenopausal osteoporosis, has been used off-label for treatment of hypoparathyroidism.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):60-2   doi:10.58347/tml.2025.1726c |  Show IntroductionHide Introduction

Talicia - A 3-Drug Combination for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
patient adherence to multidrug regimens.1 When available, susceptibility testing should be used to guide ...
The FDA has approved a fixed-dose combination of omeprazole, amoxicillin, and rifabutin (Talicia – RedHill) for treatment of Helicobacter pylori infection in adults. Talicia is the first rifabutin-based product to be approved for this indication.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-5 |  Show IntroductionHide Introduction

Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis.1 The GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist elagolix, the estrogen estradiol, and the progestin norethindrone acetate copackaged with elagolix alone, has been approved by the FDA for oral treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is the first product to be approved in the US for this indication. Elagolix (Orilissa) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis. The GnRH receptor antagonist...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):51-2 |  Show IntroductionHide Introduction

Myfembree for Fibroid-Associated Heavy Menstrual Bleeding

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021  (Issue 1630)
antagonist elagolix in combination with estradiol and norethindrone acetate, was approved earlier.1 ...
Myfembree (Myovant/Pfizer), an oral fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix, the estrogen estradiol, and the progestin norethindrone acetate, has been approved by the FDA for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is the second product to be approved in the US for this indication; Oriahnn, which contains the GnRH receptor antagonist elagolix in combination with estradiol and norethindrone acetate, was approved earlier. Relugolix was approved for...
Med Lett Drugs Ther. 2021 Aug 9;63(1630):121-3 |  Show IntroductionHide Introduction

Zavegepant (Zavzpret) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
prevention.1,2 Atogepant (Qulipta), another oral CGRP receptor antagonist, and four parenterally ...
The FDA has approved zavegepant nasal spray (Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant") to become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8   doi:10.58347/tml.2023.1681c |  Show IntroductionHide Introduction

Tofersen (Qalsody) for ALS

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
(ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. About 2% of patients ...
Tofersen (Qalsody – Biogen), an intrathecally administered antisense oligonucleotide, has received accelerated approval from the FDA for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. About 2% of patients with ALS have mutations in the SOD1 gene. Tofersen is the first drug to be approved in the US that targets a genetic cause of ALS. Accelerated approval of the drug was based on the surrogate endpoint of a reduction in plasma neurofilament light chain, which is considered likely to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4   doi:10.58347/tml.2023.1681a |  Show IntroductionHide Introduction

Omalizumab (Xolair) for Food Allergy

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
, and chronic urticaria,1,2 has now also been approved for use in conjunction with food allergen avoidance ...
Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been approved for use in conjunction with food allergen avoidance to reduce IgE-mediated food allergic reactions caused by accidental exposure in patients ≥1 year old. Omalizumab is the first drug to be approved in the US to reduce allergic reactions to more than one food. Palforzia, an oral peanut allergen powder, was approved in 2020 to mitigate allergic reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6   doi:10.58347/tml.2024.1699b |  Show IntroductionHide Introduction

In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
on days 1 to 21 of each 28-day cycle) for up to 12 cycles, followed by tafasitamab alone until disease ...
Tafasitamab-cxix (Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, in adults who are not eligible for autologous stem cell transplant. Accelerated approval was based on overall response rates.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e133   doi:10.58347/tml.2023.1682d |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
in children $1.704 1.504 14.80 189.505,6 Salicylates Aspirin – generic Bayer (Bayer) 325 mg tabs; 500 ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction